Baidu stock jumps before the bell on Ernie 5.0 launch — what traders watch next
22 January 2026
1 min read

Baidu stock jumps before the bell on Ernie 5.0 launch — what traders watch next

New York, Jan 22, 2026, 07:56 EST — Premarket

Baidu, Inc.’s shares listed in the U.S. jumped 8.2% to $162.28 in early trading Thursday, following a close at $150.03. The surge came after the company launched the official release of its Ernie 5.0 AI model during a Shanghai event. In Hong Kong, Baidu’s shares gained roughly 4%. 1

Timing is crucial for Baidu as investors now value Chinese tech stocks based on AI product rollouts, rather than solely on advertising trends. Nailing the launch is just the start. The real challenge lies in converting that into actual paid usage, and the market has shown little patience.

Baidu has long pitched itself as China’s leading AI platform player. This latest release raises questions about whether its models can attract cloud customers and developer spending, all while managing costs effectively.

China’s Xinhua news agency reported that the official Wenxin Big Model 5.0, also called Ernie 5.0, packs 2.4 trillion “parameters”—those adjustable weights crucial for learning and output. According to Xinhua, Baidu said the model is a native multimodal system, capable of processing text, images, audio, and video. It employs a sparse “mixture-of-experts” architecture, activating only a small portion of the network for each task. 2

Baidu’s AI assistant has hit 200 million monthly active users, according to the South China Morning Post, expanding its consumer base as the company rolls out its latest model. At Davos, Google DeepMind CEO Demis Hassabis noted that China’s AI models may lag U.S. rivals by about “six months” — a stark reminder of how quickly the AI race evolves and buzz can fade. 3

Baidu announced it will release its fourth-quarter and full-year 2025 earnings before U.S. markets open on Feb. 26, with a conference call scheduled for 7:30 a.m. Eastern time that same day. 4

Jefferies analyst Thomas Chong stuck with a Buy rating and pegged a $181 price target, per a TipRanks report. He’s betting Baidu Core will bounce back to sequential revenue growth as its AI-driven cloud infrastructure segment gains traction. 5

U.S. stock index futures edged up Thursday morning, showing a more positive tone in the broader market. China ADRs were also active, with Alibaba gaining ground following a Reuters report that the company is gearing up to spin off its chip division. 6

The downside is straightforward. New models can burn cash quickly if inference demand grows faster than pricing allows. Meanwhile, competitors might erode returns by slashing prices or launching similar models. If ad demand remains weak, margins will tighten further.

Traders will be closely tracking if the premarket surge sticks when U.S. markets open. Attention may then pivot from the launch to the next major event: Baidu’s Feb. 26 earnings report, which could shed light on Ernie 5.0 adoption, pricing strategies, and cloud demand.

Stock Market Today

NASA’s SPHEREx spots interstellar comet 3I/ATLAS flaring on its way out — and the chemistry surprised scientists

NASA’s SPHEREx spots interstellar comet 3I/ATLAS flaring on its way out — and the chemistry surprised scientists

7 February 2026
WASHINGTON, Feb 7, 2026, 15:17 (EST) NASA’s SPHEREx space telescope spotted interstellar comet 3I/ATLAS brightening sharply in December 2025, weeks after the comet passed closest to the sun and as it began its exit from the solar system. The infrared data showed a surge of gas and dust, including water vapor, carbon dioxide and carbon-bearing compounds, NASA said. 1 Interstellar objects are rare, and NASA says 3I/ATLAS is only the third such body confirmed, traveling on a hyperbolic path — an open orbit that does not loop back around the sun. The comet poses no threat to Earth and will
AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Novo Nordisk stock rebounds after a bruising drop as investors turn to the next catalyst
Previous Story

Novo Nordisk stock rebounds after a bruising drop as investors turn to the next catalyst

JetBlue (JBLU) stock edges up before the bell after a sharp rebound
Next Story

JetBlue (JBLU) stock edges up before the bell after a sharp rebound

Go toTop